Ex-4: exenatide-4, mTOR: mechanistic target of rapamycin, IRS1: insulin receptor substrate 1, MDS-UPDRS: Movement Disorder Society-Sponsored Revision of the Unified Parkinsons Disease Rating Scale, PD: Parkinsons disease, PKB: protein kinase B, DAergic: dopaminergic, GLP1R: glucagon-like peptide-1 receptor
The LEAN trial (Liraglutide Efficacy and Action in NASH) was a landmark study published in The Lancet (2016) demonstrating that liraglutide 1.8 mg daily led to NASH resolution in 39% of patients compared to 9% in the placebo group after 48 weeks
*This guide is for educational purposes
When you discontinue tirzepatide, appetite gradually returns to baseline over 4 to 8 weeks as the medication clears your system
At Apex MD Primary Care & Wellness Center, our approach bridges medical science and sustainable living
By promoting delta wave sleep, the deepest phase of the sleep cycle, DSIP helps individuals achieve more restorative and uninterrupted sleep